Adding bevacizumab to standard chemotherapy improves overall survival for women with ovarian cancer
the ONA take:
Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy. The researchers report overall survival was a median 5 months longer for women who received chemotherapy plus bevacizumab than for women who received chemotherapy alone. These findings were presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.
Median overall survival for women in the chemotherapy plus bevacizumab group was 42.2 months, compared with 37.3 months in the group who received chemotherapy alone. The additional drug improved progression-free survival by nearly 3.5 months (13.8 months for chemotherapy plus bevacizumab vs 10.4 months for chemotherapy alone). The ongoing study will assess quality of life in the women who also received bevacizumab and the role of secondary surgery before chemotherapy.
Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|